Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 CAR-T
- Development stage
- Phase 2
- Lead developer
- Shenzhen Binde Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NY-ESO-1 CAR-T is a type of adoptive cell therapy, specifically a Chimeric Antigen Receptor (CAR) T-cell therapy, designed to target the cancer-testis antigen NY-ESO-1 (New York esophageal squamous cell carcinoma-1). NY-ESO-1 is aberrantly expressed in various cancers but has restricted expression in healthy adult tissues, primarily germ cells in the testis and placental trophoblasts, making it an attractive target for cancer immunotherapy with minimal off-target toxicities. The CAR-T cells are genetically engineered to recognize NY-ESO-1 presented on the surface of cancer cells, leading to an immune response against the malignancy. The therapy involves infusing these engineered T cells into patients, often after lymphodepleting chemotherapy. Shenzhen BinDeBio Ltd. is developing this therapy.
- Other names
- Anti-NY-ESO-1 CAR-T cell therapyAnti-NY-ESO1 CAR-T cell therapyAnti-NY-ESO 1 CAR-T cell therapy
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 CAR-T.